VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sardar Biglari Sells 11,000 Shares

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 11,000 shares of VanEck Biotech ETF stock in a transaction on Friday, July 17th. The stock was sold at an average price of $16.71, for a total value of $183,810.00. Following the sale, the insider directly owned 3,538,961 shares of the company’s stock, valued at approximately $59,136,038.31. This trade represents a 0.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.70, for a total value of $45,908.30.
• On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.71, for a total value of $109,166.43.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.73, for a total value of $20,260.03.

VanEck Biotech ETF Stock Performance

Shares of BBH stock traded up $1.14 on Tuesday, reaching $203.43. The company had a trading volume of 7,033 shares, compared to its average volume of 5,972. The company has a 50-day moving average of $193.41 and a 200-day moving average of $192.04. VanEck Biotech ETF has a 12 month low of $155.45 and a 12 month high of $212.54.

Institutional Investors Weigh In On VanEck Biotech ETF

Several large investors have recently bought and sold shares of BBH. Empowered Funds LLC acquired a new stake in VanEck Biotech ETF in the fourth quarter worth $38,000. Flagship Harbor Advisors LLC acquired a new position in shares of VanEck Biotech ETF in the 4th quarter valued at $47,000. Allworth Financial LP grew its holdings in shares of VanEck Biotech ETF by 255.0% in the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock valued at $81,000 after buying an additional 306 shares during the period. Fifth Third Bancorp bought a new stake in shares of VanEck Biotech ETF in the 1st quarter valued at $127,000. Finally, Huntington National Bank bought a new stake in shares of VanEck Biotech ETF in the 4th quarter valued at $132,000. Institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.